Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug cocktail aims to stop leukemia relapse after transplant

NCT ID NCT05088226

First seen Apr 28, 2026 · Last updated May 24, 2026 · Updated 4 times

Summary

This study tests whether adding two drugs (ruxolitinib and chidamide) to the standard chemotherapy before a stem cell transplant can lower the chance of leukemia coming back. It involves 50 people aged 12–65 with high-risk B-cell acute lymphoblastic leukemia who have a suitable donor. The approach aims to improve disease control, but lifelong monitoring and possible medications are still needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL BLOOD STEM CELL TRANSPLANTATION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chinese PLA General Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100853, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.